IL17A and myasthenia gravis: The observed time-dependent improvements in clinical outcomes—60.7% reduction in QMG scores, 58.3% in MG-QOL15, and 64.1% in MG-ADL at week 24—were paralleled by significant declines in pathogenic biomarkers, including AChR antibody titers (69.23% reduction), IL-17 levels (84.47% suppression), and Th17 cell frequency (68% decrease).